DBV Technologies S.A.

DBVT: 10-Q · periodic report

DBV Technologies reported a net loss of $98.0 million for the six months ended June 30, 2026, compared to a loss of $69.0 million in the prior-year period, driven by increased investments in commercial readiness and regulatory preparation. As of June 30, 2026, the company held $174.9 million in cash and cash equivalents, and management estimates this funding is sufficient to support operations into the third quarter of 2027. The company provided a regulatory update, stating that the Biologics License Application (BLA) submission for the VIASKIN Peanut patch for children aged 4 through 7 is now anticipated in the third quarter of 2026. This adjustment follows iterative engagement with the FDA regarding data organization and formatting, with the agency not requesting additional clinical data. To support potential commercialization, DBV signed a letter of intent with Fareva Amboise for commercial-scale manufacturing and another with Integrated Commercialization Solutions for U.S. distribution services. The company also finalized an eight-year Manufacturing Supply Agreement with Fareva La Vallée for the exclusive supply of peanut source material.

SEC 10-Q•3mo ago

DBVT: 8-K · amendment

DBV Technologies S.A. (DBVT) held its Annual General Meeting on June 3, 2026, where shareholders approved routine corporate governance proposals, including the renewal of the board of directors and the appointment of Philina Lee as a director. The shareholders also amended the company’s bylaws to comply with new French regulations regarding the Ordinary Share Record Date and to introduce a mandatory age limit of 70 years for the Chief Executive Officer. All 39 proposals presented at the meeting were approved, including the authorization for the board to repurchase shares and issue new equity securities, reflecting standard administrative and governance maintenance rather than strategic shifts.

SEC 8-K•4mo ago